Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.03)
# 1,390
Out of 4,732 analysts
95
Total ratings
41.51%
Success rate
2.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $61.53 | +46.27% | 14 | Dec 12, 2024 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $91.84 | -12.89% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $9.33 | - | 1 | Nov 14, 2024 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $422.00 | +13.74% | 19 | Nov 5, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $681.58 | +48.92% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $272.11 | +48.84% | 2 | Oct 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $50 | $56.29 | -11.17% | 8 | Oct 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $246.27 | -10.67% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $8.01 | +24.84% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $6.01 | +8.15% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $40.53 | +77.65% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Dec 12, 2024
Reiterates: Overweight
Price Target: $90
Current: $61.53
Upside: +46.27%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $91.84
Upside: -12.89%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $9.33
Upside: -
Vertex Pharmaceuticals
Nov 5, 2024
Reiterates: Overweight
Price Target: $480
Current: $422.00
Upside: +13.74%
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $681.58
Upside: +48.92%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $272.11
Upside: +48.84%
Bristol-Myers Squibb Company
Oct 18, 2024
Reiterates: Neutral
Price Target: $50
Current: $56.29
Upside: -11.17%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $246.27
Upside: -10.67%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.01
Upside: +24.84%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $6.01
Upside: +8.15%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $40.53
Upside: +77.65%